Your reasoning is on the money, but your math isn't. If there are half a billion shares outstanding, the share price would be $2 if you have a billion dollar market cap.
If we work backwards and say what do we need in shares to reach a $4 price and achieve the Nasdaq with a $1 billion market cap, it would be 250 million shares outstanding, roughly 100 million more than are outstanding today. Of course we can look at a $.5 billion market cap and a $4 price, and that would take 125 million shares outstanding, somewhat less than are currently outstanding.
It's my belief that if we have proof of ownership of our intellectual property and one trial advanced far enough to show efficacy in a product that has patent approvals, we should gain a market cap that's a half billion or more. To me, that says that if things are truly progressing, we could be there late this year, or almost certainly next year. We could gain the Nasdaq by then without any reverse split at all, but we need some patent approvals, as well as trials that demonstrate we've right about what cannabis can do. Preclinical results may show tremendous achievement whether they're done with human tissue, or other animals, but all that's really meaningful must be done in live human trials with patients who have the condition the drug is targeted at. I don't know why our cream couldn't have been Phase 1 tested with people with psoriasis, but clearly it wasn't.
Most of the biotechs I've invested in are working on cancer and in every case the Phase 1 Trials were in the cancer they were targeting. I frankly feel for those who enter Phase 1 Trials early in the trial as they usually begin with doses so low they cannot possibly achieve benefits. Typically if they're effective it's after multiple dose escalations, often over a year into the Phase 1 Trial as cancer trials go very slowly to assure safety of the chemo being tested. Perhaps our trials with cannabis based products can advance much faster,
Current prices could truly be a great opportunity if they don't do a huge reverse split, but if they do, it will be a tough road for investors who's holdings average anything over a quarter, or perhaps less. Personally I'm holding off adding cheaper shares until I see a floor firmly established.
Gary
If we work backwards and say what do we need in shares to reach a $4 price and achieve the Nasdaq with a $1 billion market cap, it would be 250 million shares outstanding, roughly 100 million more than are outstanding today. Of course we can look at a $.5 billion market cap and a $4 price, and that would take 125 million shares outstanding, somewhat less than are currently outstanding.
It's my belief that if we have proof of ownership of our intellectual property and one trial advanced far enough to show efficacy in a product that has patent approvals, we should gain a market cap that's a half billion or more. To me, that says that if things are truly progressing, we could be there late this year, or almost certainly next year. We could gain the Nasdaq by then without any reverse split at all, but we need some patent approvals, as well as trials that demonstrate we've right about what cannabis can do. Preclinical results may show tremendous achievement whether they're done with human tissue, or other animals, but all that's really meaningful must be done in live human trials with patients who have the condition the drug is targeted at. I don't know why our cream couldn't have been Phase 1 tested with people with psoriasis, but clearly it wasn't.
Most of the biotechs I've invested in are working on cancer and in every case the Phase 1 Trials were in the cancer they were targeting. I frankly feel for those who enter Phase 1 Trials early in the trial as they usually begin with doses so low they cannot possibly achieve benefits. Typically if they're effective it's after multiple dose escalations, often over a year into the Phase 1 Trial as cancer trials go very slowly to assure safety of the chemo being tested. Perhaps our trials with cannabis based products can advance much faster,
Current prices could truly be a great opportunity if they don't do a huge reverse split, but if they do, it will be a tough road for investors who's holdings average anything over a quarter, or perhaps less. Personally I'm holding off adding cheaper shares until I see a floor firmly established.
Gary
